SUNP
Sun Pharma delivered in-line revenue and EBITDA in 1QFY27, while adjusted PAT beat expectations. Specialty and branded portfolios led the way, and the company remains on track to complete the Organon acquisition by 4QFY27.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
